Key TakeawaysHims & Hers Health shares declined Tuesday after Eli Lilly said it would be offering a lower-priced version of its popular Zepbound weight-loss treatment.Lilly explained that the new product would be sent directly to consumers.Hims & Hers recently began offering a copycat version of Novo Nordisk's Wegovy and Ozempic, and planned to have one for Zepbound in the near future. Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs ...